Zoetis announced on March 25, 2025, the results from the first clinical trial comparing Librela® (bedinvetmab) to meloxicam for managing canine osteoarthritis (OA) pain. The study, published in Frontiers in Veterinary Science, found that Librela provided equivalent pain relief to the nonsteroidal anti-inflammatory drug (NSAID) meloxicam.
The eight-week randomized study, conducted across eight primary care veterinary practices in the United Kingdom, enrolled 101 dogs. Librela demonstrated efficacy comparable to meloxicam starting at day 14 and was associated with fewer adverse events (AEs).
Professor Innes, RCVS Specialist, Movement Referrals, noted that these results provide valuable data for clinicians and pet owners in making treatment decisions. This new information supports existing guidelines recommending both Librela and NSAIDs as first-line therapies for OA pain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.